

2007

## Enterobacter Sakazakii: an Emerging Microbe With Implications for Infant Health

N. R. Mullane

B. Healy

Ciara Walsh

Technological University Dublin, ciara.walsh@tudublin.ie

See next page for additional authors

Follow this and additional works at: <https://arrow.tudublin.ie/schfsehart>



Part of the [Food Science Commons](#)

### Recommended Citation

Mullane, N. R., Walsh, C. et al. (2007) Enterobacter Sakazakii: an Emerging Microbe With Implications for Infant Health. *Minerva Paediatrica* 59:137-148, 2007. doi : 10.21427/krf1-v746

This Article is brought to you for free and open access by the School of Food Science and Environmental Health at ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact [arrow.admin@tudublin.ie](mailto:arrow.admin@tudublin.ie), [aisling.coyne@tudublin.ie](mailto:aisling.coyne@tudublin.ie).



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 4.0 License](#)

---

**Authors**

N. R. Mullane, B. Healy, Ciara Walsh, C. Iversen, P. Whyte, P. G. Wall, T. Quinn, and Seamus Fanning

Minerva paediatrica review

***Enterobacter sakazakii*: an emerging microbe with implications for infant health**

N. R. Mullane, B. Healy, C. Walsh, C. Iversen<sup>□</sup>, P. Whyte, P.G. Wall<sup>¶</sup>,  
T. Quinn and S. Fanning

Centre for Food Safety. School of Agriculture, Food Science and Veterinary Medicine, School of Public Health & Population Sciences<sup>¶</sup>, University College Dublin, Belfield, Dublin 4, Ireland and Nestle Research Centre<sup>□</sup>, Lausanne, Switzerland.

Corresponding author:

Professor Séamus Fanning,  
Centre for Food Safety,  
School of Agriculture, Food Science and Veterinary  
Medicine,  
University College Dublin,  
Belfield,  
Dublin 4, Ireland.

Tel.: (+353-1) 716 6082

Fax: (+353-1) 716 6091

[sfanning@ucd.ie](mailto:sfanning@ucd.ie)

**Key Words:** *Enterobacter sakazakii*, meningitis

## **Introduction**

*Enterobacter sakazakii* is a motile peritrichous, Gram-negative non-spore forming facultative anaerobic bacillus belonging to the family Enterobacteriaceae, genus *Enterobacter*. The microbe was listed as a new species in 1980 [1]. Using DNA-DNA hybridisation and biochemical tests Farmer et al. defined the species and identified fifteen distinct biogroups[1] with a new biogroup being added recently[2]. Based on genotyping and biotyping *E. sakazakii* represents a genetically diverse and taxonomically ill-defined species[2-5].

*Enterobacter sakazakii* is recognised as an emerging opportunistic pathogen and is the aetiological agent in rare cases of meningitis, necrotising enterocolitis and bacteremia in infants[6-15]. Since the first case of meningitis in an infant was described in England in 1958[16], neonatal infections involving *E. sakazakii* have been reported from all parts of the developing world with many of these resulting in the deaths of more than seventy infants

### **Table 1.**

Sources of *E. sakazakii* illness have not been extensively investigated and therefore the origin of the bacterium remains unknown. However, several reports have implicated contaminated powdered infant formula (PIF) as a source of *E. sakazakii* in neonatal infection[8, 14, 17, 18]. In 2004, several high profile recalls of PIF contaminated with *E. sakazakii* from Asia, South America and Europe (WHO/FAO, 2006) occurred.

These developments have focused attention on this pathogen, by both the PIF manufacturers and the health professionals. A revision of the microbiological standards applied by PIF producers has taken place, with the implementation of updated testing requirements, underpinned by legislation, aimed at reducing the risk of dissemination of the pathogen through powdered products. Attention has also focused on the development of guidelines for the correct preparation of PIF in hospitals and in homes.

This review will describe the microbiology of *E. sakazakii*, provide an understanding of its epidemiology and examine its role in public health. We will also aim to highlight the issues surrounding the proper reconstitution of PIF prior to the feeding of infants.

### **Taxonomy and background of *Enterobacter sakazakii***

*Enterobacter sakazakii* was originally referred to as a “yellow-pigmented” *Enterobacter cloacae*. It was subsequently re-defined as a new bacterial species in 1980[1]. Farmer et al.,[1] originally described 15 biogroups including 57 strains, based on biochemical profiles with five strains used to define the species by DNA-DNA hybridisations. These data suggested that the biogroups may represent more than one species and that *E. sakazakii* was 41-54% related to *Enterobacter* and *Citrobacter* species. Detailed phylogenetic analysis of 16S rDNA and *hsp60* genes confirmed the diverse heterogeneity that existed between strains and further analysis of these gene sequences showed the presence of four distinct genetic clusters, all of which

contained strains of clinical origin[3-5]. In a recent extension of the initial study [1], Iversen et al.,[2] analysed 189 strains using geno- and phenotypic methods and showed that a new biogroup (known as biogroup 16) could be defined. Further analysis determined that biogroup 1 included 32% of all known strains, whilst genogroup 1 was the largest and most genetically diverse cluster containing 90% of the studied strains and representing biogroups 1-5, 7-9, 11, 13 and 14.

No evidence has been presented to suggest that there may be differences in the virulence capacity of any one genomo- or biogroup. Therefore for the purposes of diagnosis, all 16 biogroups should be considered as potential threats to infant health.

### **Infection and epidemiology**

Infections resulting from *E. sakazakii* are rare. Nevertheless, they are a serious cause of fatal meningitis, necrotising enterocolitis and bacteremia in infants. Interestingly, although *E. sakazakii* infections (including osteomyelitis and bacteremia) have been reported in immunocompromised elderly patients[19, 20], infants appear to be the group at particular risk with neonates, especially those born prematurely or of low birth weight (< 2,500 g) reported to be in the highest risk category[20, 21]. In a recent risk analysis of 46 clinical cases two groups were identified,

- (a) those infants born close to gestation age and of normal birth weight, and who developed meningitis in the neonatal period and

(b) premature infants, who developed bacteremia after one month of age[22]. The differences in the apparent timing of disease onset was likely due to the infant feeding practices wherein, premature infants are normally fed using sterile formula only, whilst full term babies consume prepared PIF. However, this may be an over simplification, since, immuno-compromised infants up to 10 months have developed blood stream infections and formerly healthy infants have developed meningitis after the neonatal period. Furthermore asymptomatic infants have demonstrated stool carriage for up to 18 weeks[9]. **Based on current estimates, one in 100,000 births may be infected with *E. sakazakii*.**

The clinical outcomes of infants with meningitis compared those with bacteremia differs as the later generally result in a better prognosis (mortality rate of 10%)[22]. Conversely, those with meningitis often develop clinical complications including ventriculitis, seizures, brain abscess, cerebral infarction and cyst formation. Mortality rates of up to 80% have been reported[20] and these infections often associated with significant morbidity. Ninety-four % of meningitis survivors can develop neurological sequelae, including hydrocephalus, quadriplegia, impaired sight and hearing, and retarded neural development. Early intervention is critical, and computed tomography or magnetic resonance imaging is recommended to identify cerebral abnormalities in suspected cases of meningitis.

### **Origin and transmission of *E. sakazakii***

*Enterobacter sakazakii* is a ubiquitous organism found in a variety of foods. It has been cultured from a range of foods including; dried baby food, milk powder, cheese, sausage meat, vegetables, dry food ingredients, rice, lettuce, sour tea, bread and herbs and spices and PIF[21, 23, 24]. The bacterium has also been isolated from both environmental and clinical sources.

Documented environmental sources include house holds, food factories and PIF manufacturing facilities[23, 25]Mullane in submission]. Microbiological analysis of surface water, rotting wood, soil, grain, bird droppings, domestic animals, livestock and cows milk failed to yield a positive *E. sakazakii* [26]. Clinical sources have provided culture positive samples from cerebrospinal fluid (CSF), blood, bone marrow, septum, urine, inflamed appendix tissue, intestinal and respiratory tracts, eye, ear, wounds, stools and from a physicians stethoscope [Adamson 1981, Farmer 1980, [11, 21].

The existence of a primary reservoir (if any) remains to be determined although it has been postulated that the bacterium's natural habitat may be associated with plant material, based on some of the physiological characteristics of the bacterium, such as its yellow pigment, that can afford a measure of protection against harmful ultra-violet light [24]Mullane, 2006).

In epidemiological studies, PIF has been acknowledged as the vehicle of transmission for *E. sakazakii*. A strong association has been described evident between the consumption of contaminated PIF and infection in infants[8, 14, 17, 27] France 2004]. Prevalence studies in PIF have been

performed[24, 28] FDA, 2003]. Muyltjens et al. [28] inspected 141 PIF's from 35 countries and isolated *E. sakazakii* at a frequency of 14.2% representing 13 countries. The organism was recovered from powdered samples at levels ranging from 0.36 through 0.66 CFU in 100 g samples . More recently the WHO reported a prevalence of <1.8% in 6 out of the 12 unrelated studies (WHO, 2006).

The first cases of *E sakazakii* infection linked to the consumption of reconstituted PIF were reported in 1988 and involved four infants [REF]. Since then sporadic cases and outbreaks have been attributed to the consumption of contaminated PIF (**Table 1**). A review of 48 *E. sakazakii* cases since 1961 revealed that at least 25 were directly linked to the consumption of PIF, and PIF was also identified in 85% of these cases as the potential source (WHO, 2004). Similar investigations found *E. sakazakii* in a blender used for the preparation of PIF (Noriega 1990). In 1983, six infants died following the ingestion of contaminated PIF. Importantly, in this case, the organism was cultured from the PIF previously fed to these infants, along with a dish brush used for bottle cleaning and from a spoon used for preparation[13].

An outbreak in Tennessee in 2001 was the first occasion whereby infection was attributed and linked to previously unopened cans belonging to the same batch of powder[27]. In Belgium in 2002, an infant died of *E. sakazakii* meningitis following consumption of contaminated PIF (FDA). A follow up investigation identified low cell numbers of *E. sakazakii* and the implicated

formula subsequently was withdrawn. In New Zealand in 2004, a premature infant died following *E. sakazakii* meningitis, the bacterium was isolated from four asymptomatic infants in the same neonatal intensive ward and PIF was identified as the source of infection. In December 2004, contaminated PIF triggered a worldwide product recall following a possible link to two fatal cases of *E. sakazakii* meningitis in France (Wan, 2004).

More recently-----Niall I'll chat to you about this one!

### **Resistance to antimicrobials**

When a case of *E. sakazakii* infection is identified, it is important to treat the infection as quickly as possible. Successful chemotherapeutic intervention requires that the target organism is susceptible to the antimicrobial agents used. Similar to other members of *Enterobacteriaceae* *E. sakazakii* is susceptible to a range of antimicrobials of different classes, including: aminoglycosides, anti-folates, chloramphenicol, carbapenems, nitrofurantoin, tetracyclines and ticarcillin [1]. Some *Enterobacteriaceae* can exhibit resistance to benzylpenicillin, clindamycin, glycopeptides, lincosamides, oxacillin, all macrolide antibiotics, rifampicin, and streptogramins[2]. Mullane et al[unpublished] tested XX strains against a panel of 25 antibiotics and found that the majority were highly susceptible. *Enterobacter sakazakii* have been reported to be capable of inactivating cephalothin, sulfamethoxazole, and third generation cephalosporin antibiotics. Resistance to antibiotics like ampicillin has arisen from the production of  $\beta$ -lactamases and also the ability of many *Enterobacteriaceae* to alter membrane permeability through the

production of membrane porins, thereby reducing the intracellular concentration of the drugs [3]. Multidrug treatments should be taken into consideration for treatment of infections, while newer antibiotics such as trimethoprim-sulfamethoxazole have been found to be successful [5].

Disinfection, we need a few lines to review the AEM findings in relation to the efficacy of disinfectants in terms of cells in planktonic state, dried onto food preparation surfaces and in biofilms.

### **Virulence and pathogenicity**

The pathogenesis of *E. sakazakii* meningitis is currently poorly defined. It is thought that infection occurs by translocation of the bacterium through the *cordus plexus* followed by invasion into the previous sterile nutrient rich cerebral matter [Iversen, 2003]. No dose-response relationships have been published but it is probable that disease progression is host dependant requiring a large initial inoculum. *In vitro* studies in suckling mice showed that of the strains tested, all were lethal at  $1 \times 10^8$  cfu [Pagotto et al.]. The infectious dose in humans is unknown. These authors also examined the production of enterotoxin. Of the 18 strains tested, 4 were found to produce enterotoxin in suckling mice.

A few lines reviewing the cell adhesion work-showing adherence to various cell lines, including Caco-2 intestinal cells and a cerebral epithelial cell line.

Recent studies indicate that the risk of infection with *E. sakazakii* can increase due to the presence of an endotoxin (bacterial derived lipopolysaccharide) in PIF. This endotoxin is heat stable and survives through the PIF production process. It is postulated that ingestion of the toxin increases the permeability of the intestinal epithelium leading to the translocation of *E. sakazakii* across the epithelium barrier [1].

Another putative virulence factor of *E. sakazakii* that has been suggested, is the production of exopolysaccharide capsular proteins (EPS), which aid in the adherence of cells to a variety of surfaces. Cells have been found attached to stainless steel surfaces in hospital environments and on the utensils being used for the PIF preparation [2]. Biofilm formation by a number of strains has also been reported and this is a defence mechanism that promotes resistance to disinfectants and sanitizing agents. Recent studies investigating the efficacy of different a range of chemical-based disinfectants used in the clinical setting have found that all were effective against planktonic cells. When cells were dried onto food preparation surfaces, the efficacy of some was reduced and when the cells were contained as a part of a biofilm, none of these agents were effective. These findings suggest that the choice of sanitising agent and where it is to be applied, may have serious consequences for the dissemination of this organisms in manufacturing, health care and home settings. Chlorine, chlorine dioxide and Tsunami 200 were all found to reduce *E. sakazakii* numbers [3]. Quaternary ammonium-based compounds were the best and these contained the active agent, n-Alkyl dimethyl (60% C14, 30% C16, 5% C12, 5% C18), benzyl ammonium

chlorides and n-Alkyl dimethyl ethylbenzyl ammonium chlorides.

Environments of high alkalinity can lyse the membrane of Gram-negative bacteria, which results in leakage of the cytoplasm and death of the cell.

Quaternary ammonium compound disinfectants could be used on all surfaces and preparation equipment for PIF [4].

Successful adherence to a target cell is likely the first step in the infection pathway. Mange *et al.*, investigated the ability of different *E. sakazakii* strains to colonize two intestinal epithelial cell lines, Hep-2 and Caco-2 and the microvascular endothelial cell line HBMEC. Adherence to these cells was maximal at late exponential phase, with a 10-fold increase reported during this period of growth [Mange *et al.*].

All *Enterobacteriaceae* possess efflux pumps that can extrude a range of xenobiotic compounds from the cell cytoplasm. In *Salmonella*, *Campylobacter* and other enteric organisms, bile acids are a natural substrate for these membrane bound complexes. Active efflux is a recognised virulence mechanism which contributes to the survival of these pathogens in the host gastrointestinal tract. Further, they also contribute to resistance facilitating the bacterium's survival in the presence of sanitizers and disinfectants [4]. Little is known about the involvement of efflux in *E. sakazakii*.

### **Laboratory identification of *E. sakazakii***

Suitable detection methods are required to reliably isolate and distinguish between *E. sakazakii* and other closely related *Enterobacteriaceae* that can

be found in PIF (REF). At present there is no internationally validated protocol for the specific detection of *E. sakazakii*. However, selective microbiological culture media has been formulated based on the inclusion of either a chromogenic or fluorogenic substrate for an enzyme  $\alpha$ -glucosidase[29-33] [http://www.aeslaboratoire.com/cgi-bin/go\\_produits.pl](http://www.aeslaboratoire.com/cgi-bin/go_produits.pl), ISO). Currently an ISO method (DTS 22964) which is being evaluated, incorporates one such selective agar. Initially, a pre-enrichment step is carried out, whereby the PIF is enriched in buffered peptone water, followed by enrichment in modified lauryl sulphate broth (mLST). A 100 ml volume is then surface plated onto a selective agar. Confirmation is performed by **(a)** streaking presumptive colonies to TSA and examining them for their characteristic “yellow pigment” production and **(b)** biochemical confirmation using the API20E or API32E identification galleries(bioMérieux, France. This approach has been adopted and is now being implemented as part of the revised EU microbiological criteria (EC 852/2004) for PIF. However, it should be noted that  $\alpha$ -glucosidase negative *E. sakazakii* strains have been identified[32] and there are also other  $\alpha$ -glucosidase positive Enterobacteriaceae[24] both of which could result in errors in diagnosis. Furthermore, Iversen et al. (2006) recently reported that 2% of *E. sakazakii* strains surveyed failed to produce a yellow pigment on TSA[34] while others questioned the reliability of API test systems[29, 32].

As an aid to facilitate the confident identification of *E. sakazakii*, several molecular-based methods have been published molecular based. Some of these are based on the detection of conserved regions of the *E. sakazakii*

genome [35-37] Hassan 2006, Malorny, 2005]. One such method reported by Seo and Brackett, 2005 targeted the macromolecular synthesis (MMS) operon and discriminated *E. sakazakii* from 68 *Enterobacter* and 55 non-*Enterobacter* strains tested[37].

Currently the Codex Alimentarius Commission is conducting a risk assessment on the microbiological safety and safe preparation of infant formula. This Commission is reviewing the code of hygienic practice for foods for infants and children, and a microbiological criteria has been set which requires the absence of *E. sakazakii* in 10 g of powder has been introduced by the European Commission (EC 2073:2005) (WHO, 2004&2006, [http://www.fsai.ie/legislation/food/eu\\_docs/Food\\_hygiene/Reg2073\\_2005.pdf](http://www.fsai.ie/legislation/food/eu_docs/Food_hygiene/Reg2073_2005.pdf) L338/11).

These microbiological criteria provide product specification guidance to PIF manufacturers on the acceptability of their product and should form part of good hygienic practice regime during manufacturing, handling and distribution processes.

### **Molecular surveillance of *E. sakazakii***

Molecular typing methods have long been used to fingerprint clinical Enterobacteriaceae isolates associated with nosocomial infections. Application of these methods aided our understanding of bacterial epidemiology, and are regarded as useful tools to monitor food borne disease. The basis of these sub-typing methods relies on the fact that identical isolates share highly similar or indistinguishable DNA profiles or fingerprints, to link or rule out particular strains in outbreak investigations.

Pulsed-field gel electrophoresis (PFGE) has long been recognized as a gold standard in molecular sub-typing. PFGE has been used to investigate the relationship among recovered *E. sakazakii* strains isolated from formula to those cultured from infected infants[9] (**and smeets 1998**). Other typing protocols, including ribotyping and random amplification of polymorphic DNA (RADP) have also been used to similar effect[38]. Despite the frequent use of PFGE in clinical settings, the food industry has been slower to embrace this approach. Nevertheless, PFGE is now beginning to form an important part of the surveillance plan, wherein it can provide a useful backup to HACCP plans aimed at limiting transmission of spoilage and pathogenic food borne organisms. **Add two lines to update your findings.**

### **Food Safety and Public Health Implications of *E. sakazakii***

It is important to understand that PIF is not a microbiologically sterile product. Reconstitution and subsequent handling and storage must recognise the importance of maintaining temperature control, preventing the rapid growth of potential contaminating *E. sakazakii*. However, commercially available ready-to-feed liquid infant formula is sterile. PIF (like dried bovine milk and milk products) has been previously documented as a potential source of bacterial pathogens such as *Bacillus* spp., *Clostridium* spp., *Staphylococcus* spp. and Enterobacteriaceae, notably *E. sakazakii*, (Townsend *et al.* 2006; Forsythe, 2005).

The Codex Alimentarius Commission standards recommend that infants who are not breast-fed should be provided with a suitable breast milk substitute

that is properly formulated. PIF has a water activity ( $a_w$ ) of ca. 0.2 and this carefully prepared product has been formulated so as to mimic the nutritional profile of human milk. Studies have shown that *E. sakazakii* can persist for very long periods of time in a low  $a_w$  environment which would normally exist in finished PIF product. Moreover, *E. sakazakii* was reported to be more persistent in PIF than other Enterobacteriaceae including *Salmonella* and *E. coli* (Caubilla-Barron *et al.* 2004), highlighting the fact that *E. sakazakii* is more adapted to drying stress than other genera in this family. While the frequency of intrinsic *E. sakazakii* in powdered milk is of concern, the intrinsic concentration of *E. sakazakii* in PIF typically appears to be low. It is for this reason that the prevention of possible proliferation of this pathogen *in situ* in PIF is critical. It is now recognised that PIF is epidemiologically linked to neonatal infections (Bar-Oz *et al.* 2001; Nazarowec-White and Farber, 1999; Nazarowec-White and Farber, 1997). Guidelines have been developed by FAO/WHO aimed at health care givers and those in the home, alerting them to the proper protocols for reconstituting PIF. These guidelines highlight the importance of rapid cooling and feeding of reconstituted PIF where possible. It actively discourages prolonged storage and rewarming of reconstituted formula. This approach is supported by scientific evidence which clearly shows that improper storage of contaminated reconstituted PIF (ie: temperature abuse), supports the rapid growth of *E. sakazakii*. Hygienic preparation measures therefore remain a significant critical control point in the prevention of infection of *E. sakazakii* from reconstitution PIF. A summary of these general guidelines for the reconstitution of PIF in hospitals and homes is given in Table 2.

*E. sakazakii* remains an issue of global concern to the infant formula food industry. Manufacturers are being encouraged to produce a greater range of commercially sterile formula products (particularly for high risks groups). Efforts are also being made, to reduce the concentration and prevalence of *E. sakazakii* in the manufacturing environment. This is being done through in-house environmental monitoring systems and through research programmes. The initial control of bacterial populations by the infant food industry and the prevention of any potential post process contamination during the production of PIF, should have a positive effect on the control of *E. sakazakii* in the food industry.

## **Conclusions**

*Enterobacter sakazakii* is a clinically significant pathogen of public health concern to neonates and infants. Its significance has been demonstrated by its addition to the list of notifiable diseases in New Zealand (New Zealand Ministry of Health, 2005). While the role of the broader food chain as a possible source of contamination of this pathogen remains unknown, preventative measures by carers, neonatal units and the infant food industry will remain of prominent importance in the prevention of *E. sakazakii* related infections in the near future.

## **Bibliography**

1. Farmer JJ III AM, Hickmann FW, and Brenner DJ: *Enterobacter sakazakii*: A new species of "Enterobacteriaceae" isolated from clinical specimens. *International Journal of Systematic Bacteriology* 1980;30:569-584.
2. Iversen C, Waddington M, Farmer JJ, 3rd, Forsythe SJ: The biochemical differentiation of *Enterobacter sakazakii* genotypes. *BMC Microbiol* 2006;6:94.
3. Iversen C, Waddington M, On SL, Forsythe S: Identification and phylogeny of *Enterobacter sakazakii* relative to *Enterobacter* and *Citrobacter* Species. *J Clin Microbiol* 2004;42:5368-5370.
4. Lehner A, Tasara T, Stephan R: 16S rRNA gene based analysis of *Enterobacter sakazakii* strains from different sources and development of a PCR assay for identification. *BMC Microbiol* 2004;4:43.
5. Iversen C, Lancashire L, Waddington M, Forsythe S, Ball G: Identification of *Enterobacter sakazakii* from closely related species: The use of Artificial Neural Networks in the analysis of biochemical and 16S rDNA data. *BMC Microbiol* 2006;6:28.
6. Arseni A, Malamou-Ladas E, Koutsia C, Xanthou M, Triikka E: Outbreak of colonization of neonates with *Enterobacter sakazakii*. *J Hosp Infect* 1987;9:143-150.
7. Bar-Oz B, Preminger A, Peleg O, Block C, Arad I: *Enterobacter sakazakii* infection in the newborn. *Acta Paediatr* 2001;90:356-358.
8. Biering G, Karlsson S, Clark NC, Jonsdottir KE, Ludvigsson P, Steingrimsson O: Three cases of neonatal meningitis caused by *Enterobacter sakazakii* in powdered milk. *J Clin Microbiol* 1989;27:2054-2056.
9. Block C, Peleg O, Minster N, Bar-Oz B, Simhon A, Arad I, Shapiro M: Cluster of neonatal infections in Jerusalem due to unusual biochemical variant of *Enterobacter sakazakii*. *Eur J Clin Microbiol Infect Dis* 2002;21:613-616.
10. Gallagher PG: *Enterobacter* bacteremia in pediatric patients. *Rev Infect Dis* 1990;12:808-812.
11. Gallagher PG, Ball WS: Cerebral infarctions due to CNS infection with *Enterobacter sakazakii*. *Pediatr Radiol* 1991;21:135-136.
12. Muijtjens HL, Kollee LA: Neonatal meningitis due to *Enterobacter sakazakii*. *Tijdschr Kindergeneeskd* 1982;50:110-112.
13. Muijtjens HL, Zanen HC, Sonderkamp HJ, Kollee LA, Wachsmuth IK, Farmer JJ, 3rd: Analysis of eight cases of neonatal meningitis and sepsis due to *Enterobacter sakazakii*. *J Clin Microbiol* 1983;18:115-120.
14. van Acker J, de Smet F, Muyldermans G, Bougatef A, Naessens A, Lauwers S: Outbreak of necrotizing enterocolitis associated with *Enterobacter sakazakii* in powdered milk formula. *J Clin Microbiol* 2001;39:293-297.
15. Willis J, Robinson JE: *Enterobacter sakazakii* meningitis in neonates. *Pediatr Infect Dis J* 1988;7:196-199.
16. Urmenyi AM, Franklin AW: Neonatal death from pigmented coliform infection. *Lancet* 1961;1:313-315.
17. Simmons BP, Gelfand MS, Haas M, Metts L, Ferguson J: *Enterobacter sakazakii* infections in neonates associated with intrinsic contamination of a powdered infant formula. *Infect Control Hosp Epidemiol* 1989;10:398-401.
18. Clark NC, Hill BC, O'Hara CM, Steingrimsson O, Cooksey RC: Epidemiologic typing of *Enterobacter sakazakii* in two neonatal nosocomial outbreaks. *Diagn Microbiol Infect Dis* 1990;13:467-472.
19. Hawkins RE, Lissner CR, Sanford JP: *Enterobacter sakazakii* bacteremia in an adult. *South Med J* 1991;84:793-795.

20. Lai KK: Enterobacter sakazakii infections among neonates, infants, children, and adults. Case reports and a review of the literature. *Medicine (Baltimore)* 2001;80:113-122.
21. Gurtler JB, Kornacki JL, Beuchat LR: Enterobacter sakazakii: a coliform of increased concern to infant health. *Int J Food Microbiol* 2005;104:1-34.
22. Bowen AB, Braden CR: Invasive Enterobacter sakazakii disease in infants. *Emerg Infect Dis* 2006;12:1185-1189.
23. Kandhai MC, Reij MW, Gorris LG, Guillaume-Gentil O, van Schothorst M: Occurrence of Enterobacter sakazakii in food production environments and households. *Lancet* 2004;363:39-40.
24. Iversen C, Forsythe S: Isolation of Enterobacter sakazakii and other Enterobacteriaceae from powdered infant formula milk and related products. *Food Microbiology* 2004;21:771-777.
25. Kandhai MC, Reij MW, van Puyvelde K, Guillaume-Gentil O, Beumer RR, van Schothorst M: A new protocol for the detection of Enterobacter sakazakii applied to environmental samples. *J Food Prot* 2004;67:1267-1270.
26. Muytjens HL, Kollee LA: Enterobacter sakazakii meningitis in neonates: causative role of formula? *Pediatr Infect Dis J* 1990;9:372-373.
27. Weir E: Powdered infant formula and fatal infection with Enterobacter sakazakii. *Cmaj* 2002;166:1570.
28. Muytjens HL, Roelofs-Willems H, Jaspard GH: Quality of powdered substitutes for breast milk with regard to members of the family Enterobacteriaceae. *J Clin Microbiol* 1988;26:743-746.
29. Iversen C, Druggan P, Forsythe S: A selective differential medium for Enterobacter sakazakii, a preliminary study. *Int J Food Microbiol* 2004;96:133-139.
30. Guillaume-Gentil O, Sonnard V, Kandhai MC, Marugg JD, Joosten H: A simple and rapid cultural method for detection of Enterobacter sakazakii in environmental samples. *J Food Prot* 2005;68:64-69.
31. Leuschner RG, Bew J: A medium for the presumptive detection of Enterobacter sakazakii in infant formula: interlaboratory study. *J AOAC Int* 2004;87:604-613.
32. Restaino L, Frampton EW, Lionberg WC, Becker RJ: A chromogenic plating medium for the isolation and identification of Enterobacter sakazakii from foods, food ingredients, and environmental sources. *J Food Prot* 2006;69:315-322.
33. Oh SW, Kang DH: Fluorogenic selective and differential medium for isolation of Enterobacter sakazakii. *Appl Environ Microbiol* 2004;70:5692-5694.
34. Iversen C, Forsythe SJ: Comparison of media for the isolation of Enterobacter sakazakii. *Appl Environ Microbiol* 2006.
35. Lehner A, Nitzsche S, Breeuwer P, Diep B, Thelen K, Stephan R: Comparison of two chromogenic media and evaluation of two molecular based identification systems for Enterobacter sakazakii detection. *BMC Microbiol* 2006;6:15.
36. Liu Y, Cai X, Zhang X, Gao Q, Yang X, Zheng Z, Luo M, Huang X: Real time PCR using TaqMan and SYBR Green for detection of Enterobacter sakazakii in infant formula. *J Microbiol Methods* 2005.
37. Seo KH, Brackett RE: Rapid, specific detection of Enterobacter sakazakii in infant formula using a real-time PCR assay. *J Food Prot* 2005;68:59-63.
38. Nazarowec-White M, Farber JM: Phenotypic and genotypic typing of food and clinical isolates of Enterobacter sakazakii. *J Med Microbiol* 1999;48:559-567.

Smeets, L.C., Voss, A., Muytjens, H.L., Meis, J.F.G.M., & Melchers, W.J.G. 1998. Genetische karakterisatie van *Enterobacter sakazakii*-isolaten van Nederlandse patiënten met neonatale meningitis. *Nederlands Tijdschrift voor Medische Microbiologie*, **6**: 113-115.

### **References for Public Health**

Bar-Oz, B. Preminger, A., Peleg, O., Block, C. and Arad, I. (2001)

*Enterobacter sakazakii* infection in the newborn. *Acta Paediatrica.*, 90, 356-358.

Caubilla-Barron J., Iversen C. & Forsythe S.J. (2004) The Desiccation Survival of *Enterobacter sakazakii* and Related Enterobacteriaceae. 104th ASM General Meeting, New Orleans.

Drudy, D, Mullane, N.R., Quinn, T., Wall, P.G. and Fanning, S. (2006)

*Enterobacter sakazakii*: An Emerging Pathogen in Powdered Infant Formula. *Food Safety*, 42, 996-1002.

Forsythe, S.J. (2005) *Enterobacter sakazakii* and other bacteria in powdered infant milk formula. *Maternal and Child Nutrition*, 1, 44-51.

Gurtler, J.B., Kornacki, J.L. and Beuchat, L.R. (2005) *Enterobacter sakazakii*:

A coliform of increased concern to infant health. *Internationaal Journal of Food Microbiology*, 104, 1-34.

Nazarowec-White, M. and Farber, J.M. (1999) Phenotypic and genotypic typing of food and clinical isolates of *E. sakazakii*. *Journal of Medical Microbiology*, 48, 559-567.

Nazarowec-White, M. and Farber, J.M. (1997) Incidence, survival and growth of *E. sakazakii* in infant formula. *Journal of Food Protection*, 60, 226-230.

New Zealand Ministry of Health. (2005). *Enterobacter sakazakii*. Available at:<http://www.moh.govt.nz/cd>. Accessed on the 22nd of November 2006.

Townsend, S., Caubilla Barron, J., Loc-Carillo, C. and Forsythe S. (2007) The presence of endotoxin in powdered infant formula milk and the influence of endotoxin and *E. sakazakii* on bacterial translocation in the infant rat. *Food Microbiology*, 24, 67-74.

### **References for Antimicrobial**

1. Muytjens HL, Van Der Ros-Van De Repe J. Comparative In Vitro Susceptibilities of Eight *Enterobacter* Species, with Special Reference to *Enterobacter sakazakii*. *Antimicrobial Agents and Chemotherapy*, Feb.1986; 367-370.
2. Stock I, Wiedemann B. Natural Antibiotic Susceptibility of *Enterobacter amnigenus*, *Enterobacter cancerogenus*, *Enterobacter gergoviae* and *Enterobacter sakazakii* Strains. *Clin. Microbiol. Infect.* 2002; 8: 564-578.
3. Dupont M, Pagès J-M. An Early Sensor of the Enterobacterial Outer Membrane, the OmpX, Detects the Presence of Toxic Compounds.
4. Poirel L. et al. Nosocomial spread of QnrA-mediated quinolone resistance in

*Enterobacter sakazakii*. Int J Antimicrobial Agents, 2006.

5. Lai KK. *Enterobacter sakazakii* Infections among Neonates, Infants, Children, and Adults. Medicine, 2002; 80: 113-22.

### **References for Virulence/ Pathogenicity**

1. Townsend S, Barron JC, Loc-Carrillo C, Forsythe S. The Presence of Endotoxin in Powdered Infant Formula Milk and the Influence of Endotoxin and *Enterobacter sakazakii* on Bacterial Translocation in the Infant Rat. Elsevier 2006.

2. Kim H, Ryu J-H, Beuchat, LR. Attachment of and Biofilm Formation by *Enterobacter sakazakii* on Stainless Steel and Enternal Feeding Tubes. App Environ Microbiol, Sept. 2006; 5846-5856.

3. Kim H, Ryu J-H, Beuchat, LR. Survival of *Enterobacter sakazakii* on fresh produce as affected by temperature, and effectiveness of sanitizers for its elimination. Int J Food Microbiol 2006; 111: 134-143.

4. Kim H, Ryu J-H, Beuchat, LR. Effectiveness of Disinfectants in Killing *Enterobacter sakazakii* in Suspension, Dried on the Surface of Stainless Steel and in Biofilm.

5. Nikaido H. Multidrug Efflux Pumps of Gram-Negative Bacteria. J Bacteriol Oct. 1996; 5853-5859.

7. Breeuwer P, Lardeau A, Peterz M, Joosten HM. Dessication and Heat Tolerance of *Enterobacter sakazakii*. J Appl Microbiol 2003; 95: 967-973.

8. Iversen C, Lane M, Forsythe SJ. The Growth Profile, Thermotolerance and Biofilm Formation of *Enterobacter sakazakii* Grown in Infant Formula Milk. Lett Appl Microbiol 2004; 38: 378-382.

9. Nazarowec-White M, Farber JM. Thermal Resistance of *Enterobacter sakazakii* in Reconstituted Dried-Infant Formula. Lett Applied Microbiol 1997; 24:9-13.

Pagotto FJ, Nazarowec-White M, Bidawid S, Farber JM. *Enterobacter sakazakii*: infectivity and enterotoxin production in vitro and in vivo. J Food Prot 2003 Mar; 66(3): 370-5.

Mange J-P, Stephan R, Borel N, Wild P, Kim KS, Pospischil, Lehner A. Adhesive Properties of *Enterobacter sakazakii* to Human Epithelial and Brain Microvascular Endothelial Cells. BMC Microbiol Jun 2006; 6: 58.

Iversen C, Forsythe S. Risk Profile of *Enterobacter sakazakii*, an Emergent Pathogen Associated with Infant Milk Formula. Trends Food Sci 2003; 14: 443-454.